drugset / Trial / NCT04820452
A Study of IBI302 in Patients With nAMD
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.
Timeline
- Start
- 2021-04-28
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Other |
| Subject | IBI302 | Unknown | 2 mg | Intravitreal |
| Subject | IBI302 | Unknown | 4 mg | Intravitreal |